Loading...
Immunotherapies targeting CD38 in Multiple Myeloma
Recently, the monoclonal antibody daratumumab was approved as a single agent for the treatment of patients with relapsed/refractory Multiple Myeloma (MM). Daratumumab is an antibody targeting surface molecule CD38 on myeloma cells and the agent is already widely being used based on its good tolerabi...
Na minha lista:
| Udgivet i: | Oncoimmunology |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5139636/ https://ncbi.nlm.nih.gov/pubmed/27999737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1217374 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|